Regulations.gov document
Attachment A - "Advisory Committee Briefing Document for Meridia (Sibutramine…
Supporting & Related Material · FDA-2009-P-0595 · posted Jan 28, 2011
Key facts
| Document ID | FDA-2009-P-0595-0006 |
|---|---|
| Title | Attachment A - "Advisory Committee Briefing Document for Meridia (Sibutramine HydrochloridemMonohydrate) Endocrinologic and Metabolic Drug Advisory Committee Meeting on September 15, 2010" - [Abbott Laboratories, Inc. - Comment] |
| Document type | Supporting & Related Material |
| Subtype | C-Comment (Supporting and Related Material) |
| Agency | FDA |
| Docket | FDA-2009-P-0595 |
| Posted | Jan 28, 2011 |
| Effective date | Sep 24, 2010 |
At a glance
- 1–9 Public comments on this docket
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Regulations.gov documents
Regulations.gov holds the rulemaking and other documents federal agencies post for public comment. Only agency documents are published here; public submissions are not.
Source: Regulations.gov (U.S. General Services Administration eRulemaking Program) · Source date: